Clinical trials: Pediatric Multiple Sclerosis
Pediatric Multiple Sclerosis
Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis
Most youth with MS experience symptoms such as depression and fatigue. In addition, cognitive issues, especially with attention and memory occur frequently.
- Trial name
- NCT03067025
- Testing
- Actigraphy
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Pediatric-Onset Multiple Sclerosis (POMS)
Five Times Sit-To-Stand Test for Patients with Pediatric-Onset Multiple Sclerosis
Transitioning from a sitting to a standing position is a movement essential for maintaining physical independence and functional mobility, and is necessary for performing many activities in daily life.
- Trial name
- NCT06648499
- Testing
- Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS, Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Multiple Sclerosis
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who…
- Trial name
- LemKids (NCT03368664)
- Testing
- Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon
- Where
- 13 sites in France, Italy and 4 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Pediatric-onset Multiple Sclerosis
Respiratory Functions in Pediatric-Onset Multiple Sclerosis
Pediatric-onset multiple sclerosis (POMS) is a chronic, autoimmune and inflammatory disease of the central nervous system that begins before the age of 18 years.
- Trial name
- NCT05123924
- Testing
- Evaluation of respiratory capacity, respiratory muscle strength and fatigue
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Relapsing Multiple Sclerosis (RMS)
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT04667949
- Testing
- Fingolimod 0.5mg
- Where
- 13 sites in China
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Pediatric Onset Multiple Sclerosis, ADHD Predominantly Inattentive Type
Cognitive Impairment in Pediatric Onset Multiple Sclerosis
Computer-assisted rehabilitation of attention deficits in pediatric Multiple Sclerosis and ADHD patients recruited during the study "Cognitive impairment in Pediatric Onset Multiple Sclerosis: research of biomarkers predictive of…
- Trial name
- NCT03190902
- Testing
- Attention Processing Training program (APT), nonspecific computer training (n-ST)
- Volunteers
- 36 people
- Sponsor
- Pietro Iaffaldano
Multiple Sclerosis
Adherence in Pediatric Multiple Sclerosis
Disease modifying therapies (DMT) are widely used for children and adolescents with MS. Nonetheless, many pediatric patients continue to relapse and therefore require changes in therapy.
- Trial name
- NCT02234713
- Testing
- Motivational Interview, Video Attention Control
- Where
- 13 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- The Hospital for Sick Children
Epilepsy
ESIS in Pediatric DRE
The main reason for this research study is to gain information about how the brain makes seizures by causing seizures using very small amounts of current, or electrical stimulation.
- Trial name
- NCT05469373
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Sarah Katie Ihnen
Multiple Sclerosis
Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is mainly known as a disease of young to middle adulthood but approximately 5% of all MS cases worldwide involve children that are younger than 16 years.
- Trial name
- NCT00963833
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 6 sites in Austria, Belgium and 4 more
- Volunteers
- 68 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS.
- Trial name
- NCT03870763
- Testing
- Dimethyl Fumarate, Peginterferon Beta-1a
- Where
- 23 sites in United States, Colombia and 11 more
- Volunteers
- 11 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety \& efficacy
- Trial name
- NCT02200718
- Testing
- NeuroVax, IFA Incomplete Freund's Adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Immune Response BioPharma, Inc.